Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Hualu Biological’s stock price experiences unusual movement: its project for producing 50 tons of fresh yellow cattle liver mushrooms per day is being advanced steadily and in an orderly manner according to plan
What are the market’s expectations for China Green Bio behind the stock price fluctuations?
On April 3rd, China Green Bio (300970.SZ)'s stock closed with a cumulative deviation of 30% in the daily closing prices over three consecutive trading days. According to the relevant provisions of the “Shenzhen Stock Exchange Trading Rules,” this constitutes an abnormal fluctuation in stock trading.
In response to the abnormal trading of the company’s stock, the board of directors conducted self-inspections and inquiries via phone and written communication to verify with the company’s controlling shareholder and actual controller regarding related issues. Specifically, the information previously disclosed by the company does not require correction or supplementation; the company has not found any recent public media reports that could or have already significantly impacted the company’s stock trading price or any undisclosed material information; the company’s recent operational conditions and internal and external business environments have not experienced or are not expected to experience significant changes; the company’s controlling shareholder and actual controller do not have any major matters that should be disclosed but have not been disclosed, nor are they in the planning stage; during the period of abnormal stock trading, the controlling shareholder and actual controller did not buy or sell the company’s stock; and the company has not violated fair disclosure of information.
Regarding risk warnings, the company has self-inspected and found no violations of fair information disclosure. It will strictly comply with relevant laws and regulations and earnestly fulfill its disclosure obligations. Meanwhile, the company recently disclosed an “Announcement on External Investment,” proposing to build a factory-based production project for fresh yellow cattle liver mushrooms (see Shuqing) with a daily capacity of 50 tons in Wenshan Zhuang and Miao Autonomous Prefecture, Wenshan City, Yunnan Province. At full capacity, the project can produce approximately 18,000 tons per year, with a total investment of about 200 million RMB and a planned land area of about 220 acres. As of the date of this announcement, the “Investment Agreement” has been signed, and the project is progressing as planned. However, due to the construction period required, it is not expected to have a significant impact on the company’s performance in the short term. Additionally, the company recently disclosed the “2025 Performance Forecast,” which currently does not require any revision, and the company has not provided 2025 financial data to any third party other than its audited accounting firm. The company’s stock price has experienced large short-term fluctuations; investors are advised to be cautious of investment risks, make rational decisions, and invest prudently.